Prof. C.J. Fijnvandraat PhD publications

foto

Publications Prof. C.J. Fijnvandraat PhD

Positions
Medical Specialist, Full Professor
Main activities
Education, Patient care, Research
Specialisation
Pediatric Hematology
Focus of research

Hemophilia

Sickle Cell Disease

 

2020

  • Bukkems Laura H., Heijdra Jessica M., Mathias Mary, Collins Peter W., Hay Charles R. M., Tait Robert C., Mangles Sarah, Myers Bethan, Evans G., Bailiff Benjamin, Curry Nicola, Payne Jeanette, Austin Steve, Goedhart Tine M. H. J., Leebeek Frank W. G., Meijer Karina, Fijnvandraat Karin, Chowdary Pratima, Mathôt Ron A. A., Cnossen Marjon H. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients Thrombosis and haemostasis 2020;120 (5):747-757 [PubMed]
  • Hermans C., Giangrande P. L. F., O'Mahony B., de Kleijn P., Bedford M., Batorova A., Blatný J., Jansone K., Astermark J., Crato M., D'Oiron R., Dougall A., Fijnvandraat K., Grønhaug S., Jiménez-Yuste V., Jokić M., Lobet S., Nolan B., Peyvandi F., Ryan A. European principles of inhibitor management in patients with haemophilia: Implications of new treatment options Orphanet journal of rare diseases 2020;15 (1) [PubMed]
  • Andersson Nadine G., Wu Runhui, Carcao Manuel, Claeyssens-Donadel S. golène, Kobelt Rainer, Liesner Ri, Mäkipernaa Anne, Ranta Susanna, Ljung Rolf, Auerswald G., Barnes C., Chalmers E., Chambost H., Clausen N., Dunn A. L., Escuriola Ettinghausen C., Fischer K., Fijnvandraat K., van Geet C., Hoffmann M., Kavakli K., Kenet G., Königs C., Kurnik K., Manco-Johnson M., Mancuso M. E., Molinari C., Muntean W., Nolan B., Perez Garrido R., Platokouki E., Rafowicz A., Santagostino E., Shapiro A., Thomas A., Williams M. Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia British journal of haematology 2020;190 (2):e101-e104 [PubMed]
  • Fustolo-Gunnink S. F. Not all that glitters is gold: Platelet transfusions for preterm neonate 2020. 253p. ISBN 9789463756792. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Fijnvandraat C. J., Lopriore E.; Co-supervisors: van der Bom J. G., Stanworth S. J.)
  • de Jager Nico C. B., Bukkems Laura H., Heijdra Jessica M., Hazendonk Carolien H. C. A. M., Fijnvandraat Karin, Meijer Karina, Eikenboom Jeroen, Laros - van Gorkom Britta A. P., Leebeek Frank W. G., Cnossen Marjon H., Mathôt Ron A. A., Collins P. W., Kruip M. J. H. A., Polinder S., Lock J., van Moort I., Goedhart M. C. H. J., Coppens M., Peters M., Preijers T., Brons P., van der Meer F. J. M., Schutgens R. E. G., Fischer K., Driessens M. H. E., Zwaan C. M., van Vliet I., Liesner R., Chowdary P., Keeling D. One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients Journal of thrombosis and haemostasis 2020;18 (2):295-305 [PubMed]
  • Lillicrap David, Fijnvandraat Karin, Young Guy, Mancuso Maria Elisa Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms Expert review of hematology 2020;13 (4):313-321 [PubMed]
  • Abdi A., Bordbar M. R., Hassan S., Rosendaal F. R., van der Bom J. G., Voorberg J., Fijnvandraat K., Gouw S. C. Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia a—a systematic review and meta-analysis Frontiers in immunology 2020;11 [PubMed]
  • van Velzen Alice S., Eckhardt Corien L., Peters Marjolein, Oldenburg Johannes, Cnossen Marjon, Liesner Ri, Morfini Massimo, Castaman Giancarlo, McRae Simon, van der Bom Johanna G., Fijnvandraat Karin Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study British journal of haematology 2020;189 (6):1182-1191 [PubMed]
  • Abdi Amal, Kloosterman Fabienne R., Eckhardt Corien L., Male Christoph, Castaman Giancarlo, Fischer Kathelijn, Beckers Erik A. M., Kruip Marieke J. H. A., Peerlinck Kathelijne, Mancuso Maria Elisa, Santoro Cristina, Hay Charles R., Platokouki Helen, van der Bom Johanna G., Gouw Samantha C., Fijnvandraat Karin, Hart Dan P. The factor VIII treatment history of non-severe hemophilia A Journal of thrombosis and haemostasis 2020 [PubMed]
  • van Moort Iris, Bukkems Laura H., Heijdra Jessica M., Schutgens Roger E. G., Laros-van Gorkom Britta A. P., Nieuwenhuizen Laurens, van der Meer Felix J. M., Fijnvandraat Karin, Ypma Paula, de Maat Moniek P. M., Leebeek Frank W. G., Meijer Karina, Eikenboom Jeroen, Mathôt Ron A. A., Cnossen Marjon H. Von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients Thrombosis and haemostasis 2020;120 (7):1056-1065 [PubMed]

2019

  • Klaassen Irene L. M., Sol Jeanine J., Suijker Monique H., Fijnvandraat K., van de Wetering Marianne D., Heleen van Ommen C. Are low-molecular-weight heparins safe and effective in children? A systematic review Blood reviews 2019;33:33-42 [PubMed]
  • Fustolo-Gunnink S. F., Huijssen-Huisman E. J., van der Bom J. G., van Hout F. M. A., Makineli S., Lopriore E., Fijnvandraat K. Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review Blood reviews 2019;36:1-9 [PubMed]
  • Atiq Ferdows, Fijnvandraat Karin, van Galen Karin P. M., Laros-van Gorkom Britta A. P., Meijer Karina, de Meris Joke, Coppens Michiel, Mauser-Bunschoten Eveline P., Cnossen Marjon H., van der Bom Johanna G., Eikenboom Jeroen, Leebeek Frank W. G., Coppens M., Kors A., Zweegman S., de Meris J., Goverde G. J., Jonkers M. H., Dors N., Nijziel M. R., Nieuwenhuizen L., Meijer K., Tamminga R. Y. J., van der LindenHagaZiekenhuis P. W., Ypma P. F., Eikenboom H. C. J., van der Bom J. G., Smiers F. J. W., Granzen B., Hamulyák K., Brons P., Laros‐van Gorkom B. A. P., Leebeek F. W. G., Cnossen M. H., Atiq F., Mauser-Bunschoten E. P., van Galen K. P. M., Atiq F. BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease American journal of hematology 2019;94 (8):E201-E205 [PubMed]
  • Schütte Lisette M., Cnossen Marjon H., van Hest Reinier M., Driessens Mariette H. E., Fijnvandraat Karin, Polinder Suzanne, Beckers Erik A. M., Coppens Michiel, Eikenboom Jeroen, Laros-van Gorkom Britta A. P., Meijer Karina, Nieuwenhuizen Laurens, Mauser-Bunschoten Evelien P., Leebeek Frank W. G., Mathôt Ron A. A., Kruip Marieke J. H. A. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: Protocol for a multicentre single-armed trial, the DAVID study BMJ open 2019;9 (4) [PubMed]
  • Fustolo-Gunnink Susanna F, Fijnvandraat Karin, Putter Hein, Ree Isabelle M, Caram-Deelder Camila, Andriessen Peter, d'Haens Esther J, Hulzebos Christian V, Onland Wes, Kroon André A, Vijlbrief Daniël C, Lopriore Enrico, van der Bom Johanna G Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates Haematologica 2019;104 (11):2300-2306 [PubMed]
  • Nagelkerke Sietse Q., Tacke Carline E., Breunis Willemijn B., Tanck Michael W. T., Geissler Judy, Png Eileen, Hoang Long T., van der Heijden Joris, Naim Ahmad N. M., Yeung Rae S. M., Levin Michael L., Wright Victoria J., Burgner David P., Ponsonby Anne-Louise, Ellis Justine A., Cimaz Rolando, Shimizu Chisato, Burns Jane C., Fijnvandraat Karin, van der Schoot C. Ellen, van den Berg Timo K., de Boer Martin, Davila Sonia, Hibberd Martin L., Kuijpers Taco W., Dahdah Nagib, Kone-Paut Isabelle Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease Frontiers in immunology 2019;10:185 [PubMed]
  • Meinderts Sanne M, Gerritsma Jorn J, Sins Joep W R, de Boer Martin, van Leeuwen Karin, Biemond Bart J, Rijneveld Anita W, Kerkhoffs Jean-Louis H, Habibi Anoosha, van Bruggen Robin, Kuijpers Taco W, van der Schoot Ellen, Pirenne France, Fijnvandraat Karin, Tanck Michael W, van den Berg Timo K Identification of genetic biomarkers for alloimmunization in sickle cell disease British journal of haematology 2019;186 (6):887-899 [PubMed]
  • Fustolo-Gunnink Susanna F., Fijnvandraat Karin, van Klaveren David, Stanworth Simon J., Curley Anna, Onland Wes, Steyerberg Ewout W., de Kort Ellen, D'Haens Esther J., Hulzebos Christian V., Huisman Elise J., de Boode Willem P., Lopriore Enrico, van der Bom Johanna G. Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death Blood 2019;134 (26):2354-2360 [PubMed]
  • Curley Anna, Stanworth Simon J, Willoughby Karen, Fustolo-Gunnink Susanna F, Venkatesh Vidheya, Hudson Cara, Deary Alison, Hodge Renate, Hopkins Valerie, Lopez Santamaria Beatriz, Mora Ana, Llewelyn Charlotte, D'Amore Angela, Khan Rizwan, Onland Wes, Lopriore Enrico, Fijnvandraat Karin, New Helen, Clarke Paul, Watts Timothy Randomized Trial of Platelet-Transfusion Thresholds in Neonates New England journal of medicine 2019;380 (3):242-251 [PubMed]
  • Houwing M. E., de Pagter P. J., van Beers E. J., Biemond B. J., Rettenbacher E., Rijneveld A. W., Schols E. M., Philipsen J. N. J., Tamminga R. Y. J., van Draat K. Fijn, Nur E., Cnossen M. H., Study group members AMC , Heijboer Harriet Sickle cell disease: Clinical presentation and management of a global health challenge Blood reviews 2019;37 (September) [PubMed]
  • Atiq Ferdows, Mauser-Bunschoten Eveline P., Eikenboom Jeroen, van Galen Karin P. M., Meijer Karina, de Meris Joke, Cnossen Marjon H., Beckers Erick A. M., Laros-van Gorkom Britta A. P., Nieuwenhuizen Laurens, van der Bom Johanna G., Fijnvandraat Karin, Leebeek Frank W. G. Sports participation and physical activity in patients with von Willebrand disease Haemophilia 2019;25 (1):101-108 [PubMed]
  • van Deukeren D. sirée, Mauser-Bunschoten Eveline P., Schutgens Roger E. G., Eikenboom Jeroen, Meijer Karina, Fijnvandraat Karin, Laros-van Gorkom Britta A. P., Cnossen Marjon, de Meris Joke, van der Bom Johanna G., Leebeek Frank W. G., van Galen Karin P. M. The prevalence and burden of hand and wrist bleeds in von Willebrand disease Haemophilia 2019;25 (1):e35-e38 [PubMed]
  • Klaassen Irene L. M. Venous thromboembolic disease in pediatric malignancies: Epidemiology and prevention 2019. 239p. ISBN 9789463752541. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Middeldorp S. , Fijnvandraat C. J.; Co-supervisors: van Ommen C. H. , van de Wetering M. D.)

2018

  • Loomans Janneke I, Stokhuijzen Eva, Peters Marjolein, Fijnvandraat Karin Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner Journal of clinical and translational research 2018;3 (Suppl 2):351-357 [PubMed]
  • Hazendonk H. C. A. M., Heijdra J. M., de Jager N. C. B., Veerman H. C., Boender J., van Moort I., Mathôt R. A. A., Meijer K., Laros-van Gorkom B. A. P., Eikenboom J., Fijnvandraat K., Leebeek F. W. G., Cnossen M. H. Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment Haemophilia 2018;24 (3):460-470 [PubMed]
  • Groeneveld Dafna J., Sanders Yvonne V., Adelmeijer Jelle, Mauser-Bunschoten Evelien P., van der Bom Johanna G., Cnossen Marjon H., Fijnvandraat Karin, Laros-van Gorkom Britta A. P., Meijer Karina, Lisman Ton, Eikenboom Jeroen, Leebeek Frank W. G. Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study Thrombosis and haemostasis 2018;118 (1):152-160 [PubMed]
  • Boender J., Eikenboom J., van der Bom J. G., Meijer K., de Meris J., Fijnvandraat K., Cnossen M. H., Laros-van Gorkom B. A. P., van Heerde W. L., Mauser-Bunschoten E. P., de Maat M. P. M., Leebeek F. W. G. Clinically relevant differences between assays for von Willebrand factor activity Journal of thrombosis and haemostasis 2018;16 (12):2413-2424 [PubMed]
  • Atiq Ferdows, Meijer Karina, Eikenboom Jeroen, Fijnvandraat Karin, Mauser-Bunschoten Eveline P., van Galen Karin P. M., Nijziel Marten R., Ypma Paula F., de Meris Joke, Laros-van Gorkom Britta A. P., van der Bom Johanna G., de Maat Moniek P., Cnossen Marjon H., Leebeek Frank W. G. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease British journal of haematology 2018;182 (1):93-105 [PubMed]
  • Preijers T., van Moort I., Fijnvandraat K., Leebeek F. W. G., Cnossen M. H., Mathôt R. A. A. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII Thrombosis and haemostasis 2018;118 (3):514-525 [PubMed]
  • Loomans Janneke I., Kruip Marieke J. H. A., Carcao Manuel, Jackson Shannon, van Velzen Alice S., Peters Marjolein, Santagostino Elena, Platokouki Helen, Beckers Erik, Voorberg Jan, van der Bom Johanna G., Fijnvandraat Karin Desmopressin in moderate hemophilia A patients: a treatment worth considering Haematologica 2018;103:550-557 [PubMed]
  • Sins Joep W. R., Fijnvandraat Karin, Rijneveld Anita W., Boom Martine B., Kerkhoffs Jean-Louis H., van Meurs Alfred H., de Groot Marco R., Heijboer Harriët, Dresse Marie-Françoise, Lê Phu Quoc, Hermans Philippe, Vanderfaeillie Anna, van den Neste Eric W., Benghiat Fleur S., Kesse-Adu Rachel, Delannoy André, Efira André, Azerad Marie-Agnès, de Borgie Corianne A., Biemond Bart J. Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial British journal of haematology 2018;182 (3):444-448 [PubMed]
  • Loomans Janneke I. Folding to function: Rising insights in nonsevere hemophilia A and DDAVP treatment 2018. ISBN 9789463750219. [UvA Dissertations Online] University of Amsterdam. (Supervisor: Fijnvandraat C. J.; Co-supervisor: Peters M.)
  • Stokhuijzen Eva Hemostasis: Factors that matter 2018. ISBN 9789463750950. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Fijnvandraat C. J., Meijer A. B.; Co-supervisors: Rand M. L., Peters M.)
  • Stokhuijzen Eva, Rand Margaret L., Cnossen Marjon H., Biss Tina T., James Paula D., Suijker Monique H., Peters Marjolein, van der Lee Johanna H., Peters Bram, Meijer Alexander B., Blanchette Victor S., Fijnvandraat Karin Identifying Children with HEreditary Coagulation disorders (iCHEC): A protocol for a prospective cohort study BMJ open 2018;8 (5) [PubMed]
  • Abdi Amal, Linari Silvia, Pieri Lisa, Voorberg Jan, Fijnvandraat Karin, Castaman Giancarlo Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown Seminars in thrombosis and hemostasis 2018;44 (06):568-577 [PubMed]
  • Václavů Lena, Baldew Zelonna A. V., Gevers Sanna, Mutsaerts Henri J. M. M., Fijnvandraat Karin, Cnossen Marjon H., Majoie Charles B., Wood John C., VanBavel Ed, Biemond Bart J., van Ooij Pim, Nederveen Aart J. Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease British journal of haematology 2018;180 (3):432-442 [PubMed]
  • van Galen Karin P. M., Timmer Merel, de Kleijn Piet, Leebeek Frank W. G., Foppen Wouter, Schutgens Roger E. G., Eikenboom Jeroen, Meijer Karina, Fijnvandraat Karin, Laros-van Gorkom Britta A. P., Twisk Jos W., Mauser-Bunschoten Eveline P., Fischer Kathelijn Long-Term Outcome after Joint Bleeds in von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis Thrombosis and haemostasis 2018;118 (10):1690-1700 [PubMed]
  • Limperg P. F., Joosten M. M. H., Fijnvandraat K., Peters M., Grootenhuis M. A., Haverman L. Male gender, school attendance and sports participation are positively associated with health-related quality of life in children and adolescents with congenital bleeding disorders Haemophilia 2018;24 (3):395-404 [PubMed]
  • Hazendonk H. C. A. M., Preijers T., Liesner R., Chowdary P., Hart D., Keeling D., Driessens M. H. E., Laros-van Gorkom B. A. P., van der Meer F. J. M., Meijer K., Fijnvandraat K., Leebeek F. W. G., Mathôt R. A. A., Collins P. W., Cnossen M. H. Perioperative replacement therapy in haemophilia B: An appeal to “B” more precise Haemophilia 2018;24 (4):611-618 [PubMed]
  • Preijers T., Hazendonk H. C. A. M., Liesner R., Chowdary P., Driessens M. H. E., Hart D., Keeling D., Laros-van Gorkom B. A. P., van der Meer F. J. M., Meijer K., Fijnvandraat K., Leebeek F. W. G., Collins P. W., Cnossen M. H., Mathôt R. A. A., Kruip M. J. A. H., Polinder S., Lock J., van Moort I., Heijdra J. M., Nederlof A., de Jager N., Coppens M., Peters M., Tamminga R. Y. J., Brons P., Eikenboom H. C. J., Schutgens R. E. G., Fischer K., Zwaan C. M., van Vliet I. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery Journal of thrombosis and haemostasis 2018;16 (11):2196-2207 [PubMed]
  • Nederlof Angelique, Mathôt Ron A. A., Leebeek Frank W. G., Fijnvandraat Karin, Fischer Kathelijn, Cnossen Marjon H. Positioning extended half-life concentrates for future use: a practical proposal Haemophilia 2018;24 (5):e369-e372 [PubMed]
  • Hassan Shermarke, Fijnvandraat Karin, van der Bom Johanna G., Gouw Samantha C. Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders? Seminars in thrombosis and hemostasis 2018;44 (6):531-543 [PubMed]
  • Hazendonk H. C. A. M., van Moort I., Mathôt R. A. A., Fijnvandraat K., Leebeek F. W. G., Collins P. W., Cnossen M. H. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? Blood reviews 2018;32 (4):265-271 [PubMed]
  • Makris M., Oldenburg J., Mauser-Bunschoten E. P., Peerlinck K., Castaman G., Fijnvandraat K. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH Journal of thrombosis and haemostasis 2018;16 (12):2530-2533 [PubMed]

2017

  • van Tuijn Charlotte F. J., Sins Joep W. R., Fijnvandraat Karin, Biemond Bart J. Daily pain in adults with sickle cell disease-a different perspective American journal of hematology 2017;92 (2):179-186 [PubMed]
  • Stokhuijzen Eva, Koornneef Johanna Maria, Nota Benjamin, van den Eshof Bart Laurens, van Alphen Floris Pieter Joachim, van den Biggelaar Maartje, van der Zwaan Carmen, Kuijk Carlijn, Mertens Koen, Fijnvandraat Karin, Meijer Alexander Benjamin Differences between Platelets Derived from Neonatal Cord Blood and Adult Peripheral Blood Assessed by Mass Spectrometry Journal of proteome research 2017;16 (10):3567-3575 [PubMed]
  • Sins J. W. R., Schimmel M., Luken B. M., Nur E., Zeerleder S. S., van Tuijn C. F. J., Brandjes D. P. M., Kopatz W. F., Urbanus R. T., Meijers J. C. M., Biemond B. J., Fijnvandraat K. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state Journal of thrombosis and haemostasis 2017;15 (7):1392-1402 [PubMed]
  • Preijers T., Hazendonk H. C. A. M., Fijnvandraat K., Leebeek F. W. G., Cnossen M. H., Mathôt R. A. A. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients Journal of thrombosis and haemostasis 2017;15 (9):1737-1746 [PubMed]
  • van Velzen A. S., Eckhardt C. L., Peters M., Leebeek F. W. G., Escuriola-Ettingshausen C., Hermans C., Keenan R., Astermark J., Male C., Peerlinck K., le Cessie S., van der Bom J. G., Fijnvandraat K. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study Journal of thrombosis and haemostasis 2017;15 (7):1422-1429 [PubMed]
  • Andersson Nadine G., Auerswald Günter, Barnes Chris, Carcao Manuel, Dunn Amy L., Fijnvandraat Karin, Hoffmann Marianne, Kavakli Kaan, Kenet Gili, Kobelt Rainer, Kurnik Karin, Liesner Ri, Mäkipernaa Anne, Manco-Johnson Marilyn J., Mancuso Maria E., Molinari Angelo C., Nolan Beatrice, Perez Garrido Rosario, Petrini Pia, Platokouki Helen E., Shapiro Amy D., Wu Runhui, Ljung Rolf Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment British journal of haematology 2017;179 (2):298-307 [PubMed]
  • van Galen Karin P. M., Timmer Merel A., de Kleijn Piet, Fischer Kathelijn, Foppen Wouter, Schutgens Roger E. G., Eikenboom Jeroen, Meijer Karina, Cnossen Marjon H., Fijnvandraat Karin, van der Bom Johanna G., Laros-van Gorkom Britta A. P., Leebeek Frank W. G., Mauser-Bunschoten Eveline P. Joint assessment in von Willebrand disease Validation of the Haemophilia Joint Health score and Haemophilia Activities List Thrombosis and haemostasis 2017;117 (8):1465-1470 [PubMed]
  • van Galen Karin P. M., de Kleijn Piet, Foppen Wouter, Eikenboom Jeroen, Meijer Karina, Schutgens Roger E. G., Fischer Kathelijn, Cnossen Marjon H., de Meris Joke, Fijnvandraat Karin, van der Bom Johanna G., Laros-van Gorkom Britta A. P., Leebeek Frank W. G., Mauser-Bunschoten Evelien P. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study Haematologica 2017;102 (9):1486-1493 [PubMed]
  • Loomans J. I., Eckhardt C. L., Reitter-Pfoertner S. E., Holmström M., van Gorkom B. Laros, Leebeek F. W. G., Santoro C., Haya S., Meijer K., Nijziel M. R., van der Bom J. G., Fijnvandraat K. Mortality caused by intracranial bleeding in non-severe hemophilia A patients Journal of thrombosis and haemostasis 2017;15 (6):1115-1122 [PubMed]
  • Loomans J. I., Fijnvandraat K. Mortality caused by intracranial bleeding in non-severe hemophilia A patients: reply Journal of thrombosis and haemostasis 2017;15 (8):1710-1711 [PubMed]
  • Meinderts Sanne M., Sins Joep W. R., Fijnvandraat Karin, Nagelkerke Sietse Q., Geissler Judy, Tanck Michael W., Bruggeman Christine, Biemond Bart J., Rijneveld Anita W., Kerkhoffs Jean-Louis H., Pakdaman Sadaf, Habibi Anoosha, van Bruggen Robin, Kuijpers Taco W., Pirenne France, van den Berg Timo K. Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease Blood 2017;130 (19):2121-2130 [PubMed]
  • Sins Joep W. R., Mager David J., Davis Shyrin C. A. T., Biemond Bart J., Fijnvandraat Karin Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review Blood advances 2017;1 (19):1598-1616 [PubMed]
  • Abdul S., Boender J., Malfliet J. J. M. C., Eikenboom J., Fijn van Draat K., Mauser-Bunschoten E. P., Meijer K., de Meris J., Laros-van Gorkom B. A. P., van der Bom J. G., Leebeek F. W. G., Rijken D. C., Uitte de Willige S., Coppens M., Kors A., Jonkers H., Boersma R., Beckers A., Granzen B., Tamminga J., der Linden W., Ypma F., Smiers W., Brons P., Nijziel M., Cnossen H. Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease Haemophilia 2017;23 (3):437-443 [PubMed]
  • Limperg P. F., Haverman L., Beijlevelt M., van der Pot M., Zaal G., de Boer W. A., Fijnvandraat K., Peters M., Grootenhuis M. A. Psychosocial care for children with haemophilia and their parents in the Netherlands Haemophilia 2017;23 (3):362-369 [PubMed]
  • Sins Joep W. R. Therapeutic targets in sickle cell disease 2017. 283p. ISBN 9789492683960. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Fijnvandraat C. J., van Oers M. H. J.; Co-supervisors: Biemond B. J., Kuijpers T. W.)
  • Ree Isabelle M. C., Fustolo-Gunnink Suzanne F., Bekker Vincent, Fijnvandraat Karin J., Steggerda Sylke J., Lopriore Enrico Thrombocytopenia in neonatal sepsis: Incidence, severity and risk factors PLoS ONE 2017;12 (10):e0185581 [PubMed]
  • Hartholt Robin B., van Velzen Alice S., Peyron Ivan, ten Brinke Anja, Fijnvandraat Karin, Voorberg Jan To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity Blood reviews 2017;31 (5):339-347 [PubMed]
  • Loomans J. I., van Velzen A. S., Eckhardt C. L., Peters M., Mäkipernaa A., Holmstrom M., Brons P. P., Dors N., Haya S., Voorberg J., van der Bom J. G., Fijnvandraat K. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations Journal of thrombosis and haemostasis 2017;15 (2):246-254 [PubMed]

2016

  • Hazendonk Hendrika, Fijnvandraat Karin, Lock Janske, Driessens Mariëtte, van der Meer Felix, Meijer Karina, Kruip Marieke, Gorkom Britta Laros-van, Peters Marjolein, de Wildt Saskia, Leebeek Frank, Cnossen Marjon, Mathôt Ron A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients Haematologica 2016;101 (10):1159-1169 [PubMed]
  • Holstein K., Batorova A., Carvalho M., Fijnvandraat K., Holme P., Kavakli K., Lambert T., Rocino A., Jiménez-Yuste V., Astermark J. Current view and outcome of ITI therapy - A change over time? Thrombosis research 2016;148:38-44 [PubMed]
  • Eckhardt C. L., van Velzen A. S., Fijnvandraat C. J., van der Bom J. G. Dissecting intensive treatment as risk factor for inhibitor development in haemophilia Haemophilia 2016;22 (3):e241-e244 [PubMed]
  • Sins Joep W. R., Biemond Bart J., van den Bersselaar Sil M., Heijboer H., Rijneveld Anita W., Cnossen Marjon H., Kerkhoffs Jean-Louis H., van Meurs Alfred H., von Ronnen F. B., Zalpuri Saurabh, de Rijke Yolanda B., Ellen van der Schoot C., de Haas Masja, van der Bom Johanna G., Fijnvandraat Karin Early occurrence of red blood cell alloimmunization in patients with sickle cell disease American journal of hematology 2016;91 (8):763-769 [PubMed]
  • Fustolo-Gunnink S. F., Vlug R. D., Smits-Wintjens V. E. H. J., Heckman E. J., te Pas A. B., Fijnvandraat K., Lopriore E. Early-Onset Thrombocytopenia in Small-For-Gestational-Age Neonates: A Retrospective Cohort Study PLoS ONE 2016;11 (5):e0154853 [PubMed]
  • Castaman Giancarlo, Eckhardt Corien, van Velzen Alice, Linari Silvia, Fijnvandraat Karin Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A Seminars in thrombosis and hemostasis 2016;42 (5):507-512 [PubMed]
  • Lock J., de Bekker-Grob E. W., Urhan G., Peters M., Meijer K., Brons P., van der Meer F. J. M., Driessens M. H. E., Collins P. W., Fijnvandraat K., Leebeek F. W. G., Cnossen M. H., Mathôt R. A. A., Kruip M. H., de Wildt S. N., Polinder S., Ista W. G., Hazendonk H. C. A. M., van Moort I., Steyerberg E. W., Borsboom G. J. J. M., Preijers T., Stokhuijzen E., Coppens M., Middeldorp S., Tamminga R. Y. J., Laros-van Gorkom B. A. P., Eikenboom H. C. J., Schutgens R. E. G., de Meris J., Zwaan C. M., Ramnarain S., Bosschaart-Castermans R. M. M., Rotte A. E., Koolma A., Ammerlaan A. C. J. Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment Haemophilia 2016;22 (1):e1-e10 [PubMed]
  • van Velzen Alice S. INSIGHT in risk factors and treatment of inhibitors in nonsevere hemophilia A 2016. 287p. ISBN 9789491602610. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Kuijpers T. W., Fijnvandraat C. J.; Co-supervisor: Peters M.)
  • Václavů L., van der Land V., Heijtel D. F. R., van Osch M. J. P., Cnossen M. H., Majoie C. B. L. M., Bush A., Wood J. C., Fijnvandraat K. J., Mutsaerts H. J. M. M., Nederveen A. J. In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI AJNR. American journal of neuroradiology 2016;37 (9):1727-1732 [PubMed]
  • van Galen K. P. M., Meijer K., Vogely H. C., Eikenboom J., Schutgens R. E. G., Cnossen M. H., Fijnvandraat K., van der Bom J. G., Laros-van Gorkom B. A. P., Leebeek F. W. G., Mauser-Bunschoten E. P. Joint surgery in von Willebrand disease: a multicentre cross-sectional study Haemophilia 2016;22 (2):256-262 [PubMed]
  • Hazendonk H. C. A. M., Lock J., Mathôt R. A. A., Meijer K., Peters M., Laros-van Gorkom B. A. P., van der Meer F. J. M., Driessens M. H. E., Leebeek F. W. G., Fijnvandraat K., Cnossen M. H. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications Journal of thrombosis and haemostasis 2016;14 (3):468-478 [PubMed]
  • van der Land Veronica, Mutsaerts Henri J. M. M., Engelen Marc, Heijboer Harriët, Roest Mark, Hollestelle Martine J., Kuijpers Taco W., Nederkoorn Paul J., Cnossen Marjon H., Majoie Charles B. L. M., Nederveen Aart J., Fijnvandraat Karin Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease British journal of haematology 2016;172 (2):274-284 [PubMed]
  • van Velzen Alice S., Eckhardt Corien L., Streefkerk Nina, Peters Marjolein, Hart Daniel P., Hamulyak Karly, Klamroth Robert, Meijer Karina, Nijziel Marten, Schinco Piercarla, Yee Thynn T., van der Bom Johanna G., Fijnvandraat Karin, Kamphuisen P. W., van der Bom J. G., Peerlinck K., Oldenburg J., Hay C. R. M., Santagostino E., Astermark J., Loomans J. L., van Eijkelenburg A., Jansen A. J., Kruijt C. C., van Tienoven B., van Baar A. C. G., Corten I. W., Bultje A. C., Visser G. R., Meijer K., Nijziel M., Dors N., Hamulyak K., Brons P. P., Laros-van Gorkom B. A. P., van Heerde W. L., Leebeek F. W. G., Kruip M., Cnossen M. H., Mauser-Bunschoten E. P., Fischer K., Smiers F. J., Hermans C., Schwaab R., Siegmund B., Klamroth R., Escuriola-Ettingshausen C., Königs C., Petrini P., Holmström M. The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors Thrombosis and haemostasis 2016;115 (3):543-550 [PubMed]

2015

  • Sanders Yvonne V., Fijnvandraat Karin, Boender Johan, Mauser-Bunschoten Evelien P., van der Bom Johanna G., de Meris Joke, Smiers Frans J., Granzen Bernd, Brons Paul, Tamminga Rienk Y. J., Cnossen Marjon H., Leebeek Frank W. G. Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding American journal of hematology 2015;90 (12):1142-1148 [PubMed]
  • van der Land Veronica, Zwanenburg Jaco J. M., Fijnvandraat Karin, Biemond Bart J., Hendrikse Jeroen, Mutsaerts Henri J. M. M., Visser Fredy, Wardlaw Joanna M., Nederveen Aart J., Majoie Charles B. L. M., Nederkoorn Paul J. Cerebral lesions on 7 tesla MRI in patients with sickle cell anemia Cerebrovascular diseases (Basel, Switzerland) 2015;39 (3-4):181-189 [PubMed]
  • van der Land Veronica Cerebral sequelae and vasculopathy in sickle cell disease 2015. 175p. ISBN 9789462330634. [UvA Dissertations Online] University of Amsterdam. (Supervisor: Kuijpers T. W.; Co-supervisors: Fijnvandraat C. J., Peters M.)
  • Sanders Y. V., van der Bom J. G., Isaacs A., Cnossen M. H., de Maat M. P. M., Laros-van Gorkom B. A. P., Fijnvandraat K., Meijer K., van Duijn C. M., Mauser-Bunschoten E. P., Eikenboom J., Leebeek F. W. G., Coppens M., Kors A., Nijziel M. R., Tamminga R. Y. J., Ypma P. F., Eikenboom H. C. J., Smiers F. J. W., Granzen B., Brons P. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease Journal of thrombosis and haemostasis 2015;13 (6):956-966 [PubMed]
  • Eckhardt C. L., Loomans J. I., van Velzen A. S., Peters M., Mauser-Bunschoten E. P., Schwaab R., Mazzucconi M. G., Tagliaferri A., Siegmund B., Reitter-Pfoertner S. E., van der Bom J. G., Fijnvandraat K., Kamphuisen P. W., Peerlinck K., Oldenburg J., Santagostino E., Astermark J., Streefkerk N., Loomans J. L., van Eijkelenburg A., Jansen A. J., Kruijt C. C., van Tienoven B., van Baar A. C. G., Corten I. W., Meijer K., Nijziel M. R., Dors N., Hamulyak K., Beckers E., Brons P. P., Laros-van Gorkom B. A. P., van Heerde W. L., Leebeek F., Kruip M., Cnossen M. H., Mauser-Bunschoten E., Fischer K., Smiers F. J., Hermans C., Klamroth R., Escuriola-Ettingshausen C., Königs C., Petrini P., Holmström M., Mäkipernaa A., Male C., Pabinger I., Keenan R. D., Liesner R. Inhibitor development and mortality in non-severe hemophilia A Journal of thrombosis and haemostasis 2015;13 (7):1217-1225 [PubMed]
  • van Velzen Alice S., Eckhardt Corien L., Hart Daniel P., Peters Marjolein, Rangarajan Savita, Mancuso Maria Elisa, Smiers Frans J., Khair Kate, Petrini Pia, Jiménez-Yuste Victor, Hay Charles R. M., van der Bom Johanna G., Yee Thynn T., Fijnvandraat Karin Inhibitors in nonsevere haemophilia A: outcome and eradication strategies Thrombosis and haemostasis 2015;114 (1):46-55 [PubMed]
  • van Galen K. P. M., Sanders Y. V., Vojinovic U., Eikenboom J., Cnossen M. H., Schutgens R. E. G., van der Bom J. G., Fijnvandraat K., Laros-van Gorkom B. A. P., Meijer K., Leebeek F. W. G., Mauser-Bunschoten E. P. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study Haemophilia 2015;21 (3):e185-e192 [PubMed]
  • Hazendonk Hendrika C. A. M., van Moort Iris, Fijnvandraat Karin, Kruip Marieke J. H. A., Laros-van Gorkom Britta A. P., van der Meer Felix J. M., Meijer Karina, Peters Marjolein, Schutgens Roger E. G., Zwaan Christian M., Driessens Mariette H. E., Polinder Suzanne, Leebeek Frank W. G., Mathôt Ron A. A., Cnossen Marjon H. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A Thrombosis and haemostasis 2015;114 (3):639-644 [PubMed]
  • van der Land Veronica, Hijmans Channa T., de Ruiter Marieke, Mutsaerts Henri J. M. M., Cnossen Marjon H., Engelen Marc, Majoie Charles B. L. M., Nederveen Aart J., Grootenhuis Martha A., Fijnvandraat Karin Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease British journal of haematology 2015;168 (4):553-556 [PubMed]
  • Sanders Yvonne V., Groeneveld Dafna, Meijer Karina, Fijnvandraat Karin, Cnossen Marjon H., van der Bom Johanna G., Coppens M., de Meris Joke, Laros-van Gorkom Britta A. P., Mauser-Bunschoten Eveline P., Leebeek Frank W. G., Eikenboom Jeroen, Kors A., Zweegman S., de Meris J., Goverde G. J., Jonkers M. H., Dors N., Nijziel M. R., Meijer K., Tamminga R. Y. J., van der Linden P. W., Ypma P. F., van der Bom J. G., Eikenboom J., Smiers F. J. W., Granzen B., Hamulyák K., Brons P., Laros-van Gorkom B. A. P., Cnossen M. H., Leebeek F. W. G., Sanders Y. V., Mauser-Bunschoten E. P. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease Blood 2015;125 (19):3006-3013 [PubMed]

2014

  • Raterink M, van der Land V., Fijnvandraat K., Schmand B. Cognitive functioning in young adult patients with sickle cell disease Tijdschrift voor kindergeneeskunde 2014;82 (2):70-78
  • Spackman Eldon, Sculpher Mark, Howard Jo, Malfroy Moira, Llewelyn Charlotte, Choo Louise, Hodge Renate, Johnson Tony, Rees David C., Fijnvandraat Karin, Kirby-Allen Melanie, Davies Sally, Williamson Lorna Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial European journal of haematology 2014;92 (3):249-255 [PubMed]
  • Sanders Yvonne V., de Wee Eva M., Meijer Karina, Eikenboom J., van der Bom Jeroen G., Fijnvandraat C. J. Karin, Laros-van Gorkom Britta A. P., Cnossen Marjon H., Mauser-Bunschoten Evelien P., Leebeek Frank W. G. De ziekte van von Willebrand in Nederland: de WiN-studie Nederlands tijdschrift voor geneeskunde 2014;158:A6518 [PubMed]
  • van Velzen Alice S., Peters Marjolein, van der Bom Johanna G., Fijnvandraat Karin Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review British journal of haematology 2014;166 (4):485-495 [PubMed]
  • Loomans Janneke I., Lock Janske, Peters Marjolein, Leebeek Frank W. G., Cnossen Marjon H., Fijnvandraat Karin Hemofilie Nederlands tijdschrift voor geneeskunde 2014;158:A7357 [PubMed]
  • Suijker Monique H., Roovers E. A. Lian, Fijnvandraat C. J. Karin, Dors Natasja, Rodrigues Pereira Rob, Giordano Piero C., Verkerk Paul H., Peters Marjolein Hemoglobinopathie in de 21e eeuw: incidentie, diagnose en hielprikscreening Nederlands tijdschrift voor geneeskunde 2014;158:A7365 [PubMed]
  • Haverman L., van Oers H. A., Limperg P. F., Hijmans C. T., Schepers S. A., Sint Nicolaas S. M., Verhaak C.M., Bouts A. H. M., Fijnvandraat K., Peters M., Van Rossum M. A., van Goudoever J. B., Maurice-Stam H., Grootenhuis M. A. Implementation of Electronic Patient Reported Outcomes in Pediatric Daily Clinical Practice: The KLIK Experience Clinical practice in pediatric psychology 2014;2 (1):50-67
  • Eckhardt C. L. Inhibitor development in nonsevere hemophilia A 2014. 249p. ISBN 9789461087386. [UvA Dissertations Online] University of Amsterdam. (Supervisor: Kuipers T. W.; Co-supervisors: Kamphuisen P. W., Fijnvandraat C. J., Peters M.)
  • Lillicrap D., Fijnvandraat K., Santagostino E. Inhibitors - genetic and environmental factors Haemophilia 2014;20 (Suppl. 4):87-93 [PubMed]
  • Castaman Giancarlo, Fijnvandraat Karin Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A Blood 2014;124 (15):2333-2336 [PubMed]
  • Gunnink Suzanne F., Vlug Roos, Fijnvandraat Karin, van der Bom Johanna G., Stanworth Simon J., Lopriore Enrico Neonatal thrombocytopenia: etiology, management and outcome Expert review of hematology 2014;7 (3):387-395 [PubMed]
  • Eckhardt C. L., Astermark J., Nagelkerke S. Q., Geissler J., Tanck M. W. T., Peters M., Fijnvandraat K., Kuijpers T. W. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A Journal of thrombosis and haemostasis 2014;12 (8):1294-1301 [PubMed]
  • van der Land Veronica, Heijboer Harriët, Fijnvandraat Karin Transfusions for silent cerebral infarcts in sickle cell anemia New England journal of medicine 2014;371 (19):1841 [PubMed]
  • Sanders Y. V., Giezenaar M. A., Laros-van Gorkom B. A. P., Meijer K., van der Bom J. G., Cnossen M. H., Nijziel M. R., Ypma P. F., Fijnvandraat K., Eikenboom J., Mauser-Bunschoten E. P., Leebeek F. W. G., Middeldorp S., Kors A., Zweegman S., de Meris J., Jonkers M. H., Dors N., Tamminga R. Y. J., van der Linden P. W., Gasthuis Kennemer, Eikenboom H. C. J., Smiers F. J. W., Granzen B., Hamuly K., Brons P. von Willebrand disease and aging: an evolving phenotype Journal of thrombosis and haemostasis 2014;12 (7):1066-1075 [PubMed]

2013

  • van Draat Karin Fijn Challenges in transfusion of patients with sickle cell disease Transfusion and apheresis science : official journal of the World Apheresis Association 2013;48 (2):165 [PubMed]
  • Eckhardt Corien L., van Velzen Alice S., Peters Marjolein, Astermark Jan, Brons Paul P., Castaman Giancarlo, Cnossen Marjon H., Dors Natasja, Escuriola-Ettingshausen Carmen, Hamulyak Karly, Hart Daniel P., Hay Charles R. M., Haya Saturnino, van Heerde Waander L., Hermans Cedric, Holmström Margareta, Jimenez-Yuste Victor, Keenan Russell D., Klamroth Robert, Laros-van Gorkom Britta A. P., Leebeek Frank W. G., Liesner Ri, Mäkipernaa Anne, Male Christoph, Mauser-Bunschoten Evelien, Mazzucconi Maria G., McRae Simon, Meijer Karina, Mitchell Michael, Morfini Massimo, Nijziel Marten, Oldenburg Johannes, Peerlinck Kathelijne, Petrini Pia, Platokouki Helena, Reitter-Pfoertner Sylvia E., Santagostino Elena, Schinco Piercarla, Smiers Frans J., Siegmund Berthold, Tagliaferri Annarita, Yee Thynn T., Kamphuisen Pieter Willem, van der Bom Johanna G., Fijnvandraat Karin Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A Blood 2013;122 (11):1954-1962 [PubMed]
  • Fijnvandraat Karin Haemophilia A and Bin: T. Saklatvala, editors. Factor VIII: treatment options, dosing and administration, prophylaxis and pharmacokinetics.. London: Hospital Pharmacy Europe; 2013. p. 8-10
  • Gouw Samantha C., Fijnvandraat Karin Identifying nongenetic risk factors for inhibitor development in severe hemophilia a Seminars in thrombosis and hemostasis 2013;39 (7):740-751 [PubMed]
  • van der Land Veronica, Peters Marjolein, Biemond Bart J., Heijboer Harriët, Harteveld Cornelis L., Fijnvandraat Karin Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease Thrombosis research 2013;132 (6):712-717 [PubMed]
  • Sanders Y. V., Eikenboom J., de Wee E. M., van der Bom J. G., Cnossen M. H., Degenaar-Dujardin M. E. L., Fijnvandraat K., Kamphuisen P. W., Laros-van Gorkom B. A. P., Meijer K., Mauser-Bunschoten E. P., Leebeek F. W. G., Kors A., Zweegman S., Goverde G. J., Jonkers M. H., Dors N., Nijziel M. R., Tamminga R. Y. J., van der Linden P. W., Ypma P. F., Eikenboom H. C. J., Smiers F. J. W., Granzen B., Hamulyák K., Brons P., de Goede-Bolder A., van Creveld Y. V. Sanders Reduced prevalence of arterial thrombosis in von Willebrand disease Journal of thrombosis and haemostasis 2013;11 (5):845-854 [PubMed]
  • Howard Jo, Malfroy Moira, Llewelyn Charlotte, Choo Louise, Hodge Renate, Johnson Tony, Purohit Shilpi, Rees David C., Tillyer Louise, Walker Isabeau, Fijnvandraat Karin, Kirby-Allen Melanie, Spackman Eldon, Davies Sally C., Williamson Lorna M. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial Lancet 2013;381 (9870):930-938 [PubMed]
  • Gouw Samantha C., Fijnvandraat Karin Unraveling the genetics of inhibitors in hemophilia Blood 2013;121 (8):1250-1251 [PubMed]

2012

  • Gevers Sanna, Nederveen Aart J., Fijnvandraat Karin, van den Berg Sandra M., van Ooij Pim, Heijtel Dennis F., Heijboer Harriët, Nederkoorn Paul J., Engelen Marc, van Osch Matthias J., Majoie Charles B. Arterial spin labeling measurement of cerebral perfusion in children with sickle cell disease Journal of magnetic resonance imaging 2012;35 (4):779-787 [PubMed]
  • Batorova A., Holme P., Gringeri A., Richards M., Hermans C., Altisent C., Lopez-Fernández M., Fijnvandraat K. Continuous infusion in haemophilia: current practice in Europe Haemophilia 2012;18 (5):753-759 [PubMed]
  • de Wee Eva M., Sanders Yvonne V., Mauser-Bunschoten Eveline P., van der Bom Johanna G., Degenaar-Dujardin Manon E. L., Eikenboom Jeroen, de Goede-Bolder Arja, Laros-van Gorkom Britta A. P., Meijer Karina, Hamulyák Karly, Nijziel Marten R., Fijnvandraat Karin, Leebeek Frank W. G. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease Thrombosis and haemostasis 2012;108 (4):683-692 [PubMed]
  • Fijnvandraat Karin, Cnossen Marjon H., Leebeek Frank W. G., Peters Marjolein Diagnosis and management of haemophilia BMJ (Clinical research ed.) 2012;344:e2707 [PubMed]
  • de Wee E. M., Klaij K., Eikenboom H. C. J., van der Bom J. G., Fijnvandraat K., Laros-van Gorkom B. A. P., Mauser-Bunschoten E. P., Meijer K., Goverde G., van der Linden P. W. G., Rijken D. C., Leebeek F. W. G. Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease Haemophilia 2012;18 (3):444-451 [PubMed]
  • Boelaars M. F. P., Peters M., Fijnvandraat K. Evaluation of a self-administrated pediatric bleeding questionnaire measuring bleeding severity in children Thrombosis and haemostasis 2012;108 (5):1006-1007 [PubMed]
  • Eckhardt Corien L., Mauser-Bunschoten Evelien P., Peters Marjolein, Leebeek Frank W. G., van der Meer Felix J. M., Fijnvandraat Karin Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands British journal of haematology 2012;157 (6):747-752 [PubMed]
  • Dekker Louise H., Fijnvandraat Karin, Brabin Bernard J., van Hensbroek Michael Boele Micronutrients and sickle cell disease, effects on growth, infection and vaso-occlusive crisis: A systematic review Pediatric blood & cancer 2012;59 (2):211-215 [PubMed]
  • Hijmans Channa T. Mind patterns in pediatric sickle cell disease. Evaluation of neurocognitive deficits, behavioral and emotional problems and health-related quality of llife 2012. 157p. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Kuijpers T. W., Oosterlaan J.; Co-supervisors: Grootenhuis M. A., Fijnvandraat C. J.)
  • Richards M., Lavigne Lissalde G., Combescure C., Batorova A., Dolan G., Fischer K., Klamroth R., Lambert T., Lopez-Fernandez M., Pérez R., Rocino A., Fijnvandraat K. Neonatal bleeding in haemophilia: a European cohort study British journal of haematology 2012;156 (3):374-382 [PubMed]
  • Heijboer Harriet, Fijnvandraat Catharina J. Tussen Scylla en Charybdis. Transfusies versus hydroxyureum voor de behandeling van herseninfarct bij kinderen met sikkelcelziekte. Kinderarts en Wetenschap 2012;3:35-36

2011

  • van der Land V., Suijker M. H., Cnossen M. H., Peters M., Heijboer H., Fijnvandraat K. Growth in children with sickle cell disease in the Netherlands: first results of the FOCUS study. Pediatric clinics Amsterdam 2011;22:9
  • de Wee E. M., Knol H. M., Mauser-Bunschoten E. P., van der Bom J. G., Eikenboom J. C. J., Fijnvandraat K., de Goede-Bolder A., Laros-van Gorkom B., Ypma P. F., Zweegman S., Meijer K., Leebeek F. W. G., Kamphuisen P. W., Kors A., Degenaar-Dujardin M. E. L., Goverde G. J., Jonkers M. H., Dors N., Hofhuis W. J. D., Nijziel M. R., Tamminga R. Y. J., van der Linden P. W., Eikenboom H. C. J., Smiers F. J. W., Granzen B., Hamulyák K., Brons P., Laros-van Gorkom B. A. P., Nováková I. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease Thrombosis and haemostasis 2011;106 (5):885-892 [PubMed]
  • de Wee E. M., Fijnvandraat K., de Goede-Bolder A., Mauser-Bunschoten E. P., Eikenboom J. C. J., Brons P. P., Smiers F. J., Tamminga R., Oostenbrink R., Raat H., van der Bom J. G., Leebeek F. W. G. Impact of von Willebrand disease on health-related quality of life in a pediatric population Journal of thrombosis and haemostasis 2011;9 (3):502-509 [PubMed]
  • Ubbink D. T., Vermeulen H., Knops A. M., Legemate D. A., Oude Rengerink K., Heineman M. J., Roos Y. B., Fijnvandraat C. J., Heymans H. S., Simons R., Levi M. [=Marcel M.] Implementation of evidence-based practice: outside the box, throughout the hospital Netherlands journal of medicine 2011;69 (2):87-94 [PubMed]
  • Hermans C., de Moerloose P., Fischer K., Holstein K., Klamroth R., Lambert T., Lavigne-Lissalde G., Perez R., Richards M., Dolan G., Fijnvandraat Karin Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations Haemophilia 2011;17 (3):383-392 [PubMed]
  • van der Plas Evelyn M., van den Tweel Xandra W., Geskus Ronald B., Heijboer Harriët, Biemond Bart J., Peters Marjolein, Fijnvandraat Karin Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening British journal of haematology 2011;155 (1):106-110 [PubMed]
  • Hijmans Channa T., Fijnvandraat Karin, Grootenhuis Martha A., van Geloven Nan, Heijboer Harriët, Peters Marjolein, Oosterlaan Jaap Neurocognitive Deficits in Children With Sickle Cell Disease: A Comprehensive Profile Pediatric blood & cancer 2011;56 (5):783-788 [PubMed]
  • Hijmans Channa T., Grootenhuis Martha A., Oosterlaan Jaap, Heijboer Harriët, Peters Marjolein, Fijnvandraat Karin Neurocognitive Deficits in Children With Sickle Cell Disease Are Associated With the Severity of Anemia Pediatric blood & cancer 2011;57 (2):297-302 [PubMed]
  • van Dellen Q. M., Kreier F., de Kruiff C. C., Boluyt N., Fijnvandraat K. Question 2 Does combined oral dexamethasone and epinephrine inhalation help infants with bronchiolitis to recover faster? Archives of disease in childhood 2011;96 (6):606-608 [PubMed]
  • Eckhardt C. L., van der Bom J. G., van der Naald M., Peters M., Kamphuisen P. W., Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review Journal of thrombosis and haemostasis 2011;9 (10):1948-1958 [PubMed]
  • James E. A., van Haren S. D., Ettinger R. A., Fijnvandraat K., Liberman J. A., Kwok W. W., Voorberg J., Pratt K. P. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site Journal of thrombosis and haemostasis 2011;9 (4):689-699 [PubMed]

2010

  • Jöbsis Jasper J., Fijnvandraat Karin, Stapel Steven O., Bouts Anthonia H. Anti-epoetin-antibody-induced anemia in a child with chronic renal failure Pediatric nephrology (Berlin, Germany) 2010;25 (5):993-994 [PubMed]
  • van den Tweel Xandra W., van der Lee Johanna H., Heijboer Harriët, Peters Marjolein, Fijnvandraat Karin Development and validation of a pediatric severity index for sickle cell patients American journal of hematology 2010;85 (10):746-751 [PubMed]
  • Hijmans Channa T., Fijnvandraat Karin, Oosterlaan Jaap, Heijboer Harriët, Peters Marjolein, Grootenhuis Martha A. Double disadvantage: a case control study on health-related quality of life in children with sickle cell disease Health and quality of life outcomes 2010;8 (1):121 [PubMed]
  • van Helden P. M. W., van Haren S. D., Fijnvandraat K., van den Berg H. Marijke, Voorberg J. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors Haemophilia 2010;16 (102):35-43 [PubMed]
  • Al-Saqladi Abdul-Wahab M., Harper Greg, Delpisheh Ali, Fijnvandraat Karin, Bin-Gadeem Hassan A., Brabin Bernard J. Frequency of the MTHFR C677T Polymorphism in Yemeni Children with Sickle Cell Disease Hemoglobin 2010;34 (1):67-77 [PubMed]
  • de Wee E. M., Mauser-Bunschoten E. P., van der Bom J. G., Degenaar-Dujardin M. E. L., Eikenboom H. C. J., Fijnvandraat K., de Goede-Bolder A., Laros-van Gorkom B. A. P., Meijer K., Raat H., Leebeek F. W. G. Health-related quality of life among adult patients with moderate and severe von Willebrand disease Journal of thrombosis and haemostasis 2010;8 (7):1492-1499 [PubMed]
  • van Dellen Q. M., de Kruiff C. C., Kreier Felix, Fijnvandraat Karin, Boluyt Nicole Is de combinatiebehandeling van dexamethason en adrenaline bij bronchiolitis effectief en kan hiermee ziekenhuisopname worden voorkomen? Wetenschappelijk bewijs en praktische toepassing. Praktische pediatrie 2010;4 (4):269-273
  • Klamroth R., Holstein K., von Depka M., Richards M., Lavigne-Lissalde G., Fijnvandraat K. Major haemorrhage in neonates with haemophilia Frequency and risk factors - European cohort study Hamostaseologie 2010;30 (4A Suppl. 1):S146-S147
  • Van der Plas E. M., van den Tweel X. W., Heijboer H., Geskus R. B., Biemond B. J., Peters M., Fijnvandraat K. Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. Pediatric clinics Amsterdam 2010;21 (1):5-6
  • Astermark J., Altisent C., Batorova A., Diniz M. J., Gringeri A., Holme P. A., Karafoulidou A., Lopez-Fernández M. F., Reipert B. M., Rocino A., Schiavoni M., von Depka M., Windyga J., Fijnvandraat K. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report Haemophilia 2010;16 (5):747-766 [PubMed]
  • Peters M., Fijnvandraat K., van den Tweel X. W., Garre F. G., Giordano P. C., van Wouwe J. P., Pereira R. R., Verkerk P. H. One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening Archives of disease in childhood 2010;95 (10):822-825 [PubMed]
  • Nur Erfan, Brandjes Dees P., Schnog John-John B., Otten Hans-Martin, Fijnvandraat Karin, Schalkwijk Casper G., Biemond Bart J. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients British journal of haematology 2010;151 (1):62-69 [PubMed]

2009

  • Hijmans Channa T., Grootenhuis Martha A., Oosterlaan Jaap, Last Bob F., Heijboer Harriët, Peters Marjolein, Fijnvandraat Karin Behavioral and Emotional Problems in Children With Sickle Cell Disease and Healthy Siblings: Multiple Informants, Multiple Measures Pediatric blood & cancer 2009;53 (7):1277-1283 [PubMed]
  • van den Tweel Xandra W., Nederveen Aart J., Majoie Charles B. L. M., van der Lee Johanna H., Wagener-Schimmel Laetitia, van Walderveen Marianne A. A., Poll The Bwee Tien, Nederkoorn Paul J., Heijboer Harriët, Fijnvandraat Karin Cerebral blood flow measurement in children with sickle cell disease using continuous arterial spin labeling at 3.0-Tesla MRI Stroke; a journal of cerebral circulation 2009;40 (3):795-800 [PubMed]
  • Grotenhuis H. B., Fijnvandraat K., de Kruiff C. C. Does palivizumab prophylaxe reduce hospitalization due to RSV in young children with hemodynamically significant congenital heart disease? Pediatric clinics Amsterdam 2009;20 (4):10-11
  • van den Heuvel M., de Kruiff C. C., Fijnvandraat K. Ernstige pneumonie: Is (initieel) intraveneuze behandeling beter dan orale? Praktische pediatrie 2009;3 (1):287-92
  • Eckhardt Corien L., Kamphuisen Pieter W., Fijnvandraat Karin Inhibitors of factor VIII in hemophilia New England journal of medicine 2009;361 (3):309; author reply 310 [PubMed]
  • Eckhardt C. L., Menke L. A., van Ommen C. H., van der Lee J. H., Geskus R. B., Kamphuisen P. W., Peters M., Fijnvandraat K. Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A Journal of thrombosis and haemostasis 2009;7 (6):930-937 [PubMed]
  • van der Heide M., de Kruiff C. C., Fijnvandraat K. Is hypnosis a promising treatment option for chronic abdominal pain? A search for evidence. Pediatric clinics Amsterdam 2009;20 (3):8-9
  • Oey N. A., de Kruiff C. C., Fijnvandraat K. Is prophylactic therapy indicated in the prevention of recurrent simple febrile seizures? Pediatric clinics Amsterdam 2009;20 (1):9-11
  • van den Tweel Xandra W. Measuring complications of sickle cell disease 2009. 136p. ISBN 9789090242224. [UvA Dissertations Online] University of Amsterdam. (Supervisors: Kuijpers T. W., Offringa M.; Co-supervisor: Fijnvandraat C. J.)
  • Eckhardt C. L., Menke L. M., van Ommen C. H., van der Lee J. H., Geskus R. B., Kamphuisen P. W., Peters M., Fijnvandraat K. New insights in the cause of inhibitor development in hemophilia A: the Arg593->Cys mutation and high dose of factor VIII may be the culprits. Pediatric clinics Amsterdam 2009;20 (2):8-10

2008

  • de Kruiff C. C., Bouts A. H. M., Pajkrt D., Fijnvandraat K. Antibiotica voor acute pyelonefritis bij kinderen, volledig oraal of (initieel) intraveneus behandelen? Evidence en praktische toepassing. Praktische pediatrie 2008;1 (68):64
  • Padberg R. D., Kindermann A., van Gool T., Fijnvandraat K. Blastocystic hominis gevonden! Is de buikpijn dan wel verklaard? Evidence en praktische toepassing. Praktische pediatrie 2008;9:?-?
  • Dors N., Rodrigues Pereira R., van Zwieten R., Fijnvandraat K., Peters M. Glucose-6-fosfaatdehydrogenasedeficiëntie: klinische presentatie en uitlokkende factoren Nederlands tijdschrift voor geneeskunde 2008;152 (18):1029-1033 [PubMed]
  • Al-Saqladi A.-W. M., Cipolotti R., Fijnvandraat K., Brabin B. J. Growth and nutritional status of children with homozygous sickle cell disease Annals of tropical paediatrics 2008;28 (3):165-189 [PubMed]
  • Hijmans Channa T., van Oirschot M. M., Heijboer H., Peters M., Hendriks C. J., Last B. F., Oosterlaan J., Grootenhuis M. A., Fijnvandraat K. Neuropsychological dysfunction in children with sickle cell disease: the AANPAK project. Pediatric clinics Amsterdam 2008;19:10-12
  • Hofstede F. G., Fijnvandraat K., Plug I., Kamphuisen W., Rosendaal F. R., Peters M. Obesity: a new disaster for haemophilic patients? A nationwide survey Haemophilia 2008;14 (5):1035-1038 [PubMed]
  • van den Tweel Xandra W., Hatzmann Janneke, Ensink Elske, van der Lee Johanna H., Peters Marjolein, Fijnvandraat Karin, Grootenhuis Martha Quality of life of female caregivers of children with sickle cell disease: a survey Haematologica 2008;93 (4):588-593 [PubMed]

2007

  • Bruijn M., Fijnvandraat K., Peters M., Bos A. P. De effectiviteit van de behandeling van diffuse intravasele stolling bij kinderen: een systematische review. Tijdschrift voor kindergeneeskunde 2007;5:204-210
  • Fijnvandraat K., Eikenboom J. C. J. Diagnostiek en behandeling van de ziekte van von Willebrand. Tijdschrift voor kindergeneeskunde 2007;5:191-197
  • van Helden P. M. W., Kaijen P. H. P., Fijnvandraat K., van den Berg H. M., Voorberg J. Factor VIII-specific memory B cells in patients with hemophilia A Journal of thrombosis and haemostasis 2007;5 (11):2306-2308 [PubMed]
  • Heijboer H., van den Tweel X. W., Fijnvandraat K., Peters M. Herkenning van kinderen met sikkelcelziekte in Nederland Nederlands tijdschrift voor geneeskunde 2007;151 (45):2498-501 [PubMed]

2006

  • van den Tweel Xandra, Heijboer Harriët, Fijnvandraat Karin, Peters Marjolein Identifying children with sickle cell anaemia in a non-endemic country: age at diagnosis and presenting symptoms European journal of pediatrics 2006;165 (8):581-582 [PubMed]
  • Bril Wendy S., van Helden Pauline M. W., Hausl Christina, Zuurveld Marleen G., Ahmad Rafi U., Hollestelle Martine J., Reitsma Pieter H., Fijnvandraat Karin, van Lier Rene A. W., Schwarz Hans Peter, Mertens Koen, Reipert Birgit M., Voorberg Jan Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution Thrombosis and haemostasis 2006;95 (2):341-347 [PubMed]

2004

  • eikenboom J. C., Fijnvandraat K. De ziekte van Von Willebrand type 1: de meest voorkomende, erfelijke bloedingsneiging of een milde risicofactor voor bloeding? Nederlands tijdschrift voor hematologie 2004;1:54-59
  • Bril W. S., MacLean P. E., Kaijen P. H. P., van den Brink E. N., Lardy N. M., Fijnvandraat K., Peters M., Voorberg J. HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation Haemophilia 2004;10 (5):509-514 [PubMed]
  • Goldschmidt W. F. M., de Vries H. J. C., Fijnvandraat C. J., van der Horst C. M. A. M., Sillevis Smitt J. H. Necrotiserende fasciitis bij een kind met varicella Nederlands tijdschrift voor dermatologie en venereologie 2004;14 (6):187-189
  • MacLean P. E., Fijnvandraat K., Beijlevelt M., Peters M. The impact of unaware carriership on the clinical presentation of haemophilia Haemophilia 2004;10 (5):560-564 [PubMed]

2003

  • Fijnvandraat Karin, Bril Wendy S., Voorberg Jan Immunobiology of inhibitor development in hemophilia A Seminars in thrombosis and hemostasis 2003;29 (1):61-68 [PubMed]

2000

  • Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes Blood 2000;95 (2):558-563 [PubMed]
  • Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain Blood 2000;96 (2):540-545 [PubMed]

1999

  • Acquired protein S deficiency caused by estrogen treatment of tall stature Journal of pediatrics 1999;135 (4):477-481 [PubMed]
  • Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution Thrombosis and haemostasis 1999;81 (5):723-726 [PubMed]
  • van Mourik J. A., Boertjes R., Huisveld I. A., Fijnvandraat K., Pajkrt D., van Genderen P. J., Fijnheer R. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation Blood 1999;94 (1):179-185 [PubMed]

1998

  • A human alloantibody interferes with binding of factor IXa to the factor VIII light chain Blood 1998;91 (7):2347-2352 [PubMed]
  • Hay C. R., Ludlam C. A., Colvin B. T., Hill F. G., Preston F. E., Wasseem N., Bagnall R., Peake I. R., Berntorp E., Mauser Bunschoten E. P., Fijnvandraat K., Kasper C. K., White G., Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation Thrombosis and haemostasis 1998;79 (4):762-766 [PubMed]

1997

  • Emotional adjustment of children and adolescents with haemophilia in relation to the HIV threat Haemophilia 1997;3 (1):39-45 [PubMed]
  • Fijnvandraat K., Berntorp E., ten Cate J. W., Johnsson H., Peters M., Savidge G., Tengborn L., Spira J., Stahl C. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and haemostasis 1997;77 (2):298-302 [PubMed]
  • The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A Blood 1997;89 (12):4371-4377 [PubMed]

1996

  • Keuzenkamp-Jansen C. W., Fijnvandraat C. J., Kneepkens C. M., Douwes A. C. Diagnostic dilemmas and results of treatment for chronic constipation Archives of disease in childhood 1996;75 (1):36-41 [PubMed]
  • Borchiellini A., Fijnvandraat K., ten Cate J. W., Pajkrt D., van Deventer S. J., Pasterkamp G., Meijer-Huizinga F., Zwart-Huinink L., Voorberg J., van Mourik J. A. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans Blood 1996;88 (8):2951-2958 [PubMed]

1995

  • Wuillemin W. A., Fijnvandraat K., Derkx B. H., Peters M., Vreede W., ten Cate H., Hack C. E. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock Thrombosis and haemostasis 1995;74 (6):1436-1441 [PubMed]
  • Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality Thrombosis and haemostasis 1995;73 (1):15-20 [PubMed]
  • Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way Thrombosis and haemostasis 1995;73 (3):484-487 [PubMed]
  • Fijnvandraat K., Peters M., ten Cate J. W. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels British journal of haematology 1995;91 (2):474-476 [PubMed]

1994

  • Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock Progress in clinical and biological research 1994;388:247-254 [PubMed]

1993

  • Chronische functionele obstipatie bij kinderen. Nederlands tijdschrift voor geneeskunde 1993;137:706-709

Corona-maatregelen

We zetten ons in om ons ziekenhuis veilig te houden tijdens de coronacrisis.

Lees deze extra maatregelen goed door voordat u een van onze locaties bezoekt: